CandlesenseCandlesense
MRK•benzinga•

Merck Announces Topline Results From The First Two Of Three Phase 3 Trials Evaluating The Safety And Efficacy Of Enlicitide Decanoate For Adults With Hyperlipidemia On Lipid-lowering Therapies, CORALreef HeFH and CORALreef AddOn Trials Met Their Primary

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 9, 2025 by benzinga

← Back to MRK News
Merck Announces Topline Results From The First Two Of Three Phase 3 Trials Evaluating The Safety And Efficacy Of Enlicitide Decanoate For Adults With Hyperlipidemia On Lipid-lowering Therapies, CORALreef HeFH and CORALreef AddOn Trials Met Their Primary | MRK Stock News | Candlesense